I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
Everolimus is a rapamycin analog. It is used to treat certain types of kidney cancer, breast cancer and brain tumor. It prevents transplant rejection by decreasing the activity of the immune system. It also act as a kinase inhibitor. It is used in the treatment of subependymal giant cell astrocytoma (SEGA; a type of brain tumor) in adults and children 1 year of age and older who have TSC.
Puricel, S.; Arroyo, D.; Corpataux N.; Baeriswyl, G.; Lehmann, N.; Kallinikou, Z.; Muller, O.; Allard, L.; Stauffer, J.; Togni, M.; Goy, J.; Cook, S. Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds. J. Am. Coll. Cardiol. 2015, 65 (8), 791-801.
Naruse, T.; Yanamoto, S.; Yamada, S.; Rokutanda, S.; Kawakita, A.; Kawasaki, G.; Umeda, M. Anti-Tumor Effect of the Mammalian Target of Rapamycin Inhibitor Everolimus in Oral Squamous Cell Carcinoma. Pathol. Oncol. Res. 2015, 21 (3), 765-773.
Hazard Statements: H372
Causes damage to organs through prolonged or repeated exposure.
Precautionary Statements: P260-P264-P270-P314-P501a
Do not breathe dust/fume/gas/mist/vapours/spray. Wash thoroughly after handling. Do not eat, drink or smoke when using this product. Get medical advice/attention if you feel unwell. Dispose of contents/container in accordance with local/regional/national/international regulations.